Unstable angina

Article written and reviewed by Dr Luca Moretti

Unstable angina is acute myocardial ischemia that causes symptoms at rest or with minimal activity, or a rapid worsening of pre-existing angina, without demonstrable acute myocardial injury. The boundary with NSTEMI is neither clinical nor electrocardiographic, but biomarker-based: in NSTEMI, troponin shows an acute change with at least one value above the sex-specific 99th percentile together with evidence of ischemia. A negative single troponin measurement is insufficient. The result should preferably come from a high-sensitivity assay, be interpreted in relation to time of onset, and remain negative throughout the appropriate serial pathway.
The use of high-sensitivity troponin assays has markedly narrowed this diagnosis. Many cases that were called unstable angina with CK-MB or less sensitive tests are now small NSTEMIs; the residual category has a lower average risk, but still includes patients with critical stenosis, transient thrombus, or dynamic ischemia. The term should not be used as a catch-all for every instance of chest pain with normal initial tests. It requires a convincing probability of ischemia and adequate exclusion of acute myocardial injury.

Assessment aims to recognize three scenarios: high-risk active ischemia requiring urgent coronary angiography; a suspected stable but non-necrotic coronary syndrome to be investigated during hospitalization; and low-probability pain for which an accelerated pathway may permit safe discharge. Serial ECG findings, symptom characteristics, previous coronary artery disease, troponin, and hemodynamic status are more important than the initial label. The final diagnosis may change after angiography, coronary CT angiography, functional testing, or the appearance of biomarkers.

Etiology, risk factors, pathogenesis, and pathophysiology

The classic mechanism is a complicated plaque with a nonocclusive or rapidly lysed platelet thrombus. Rupture, erosion, and a calcified nodule expose thrombogenic surfaces; the thrombus grows and regresses, transiently reducing flow without producing detectable necrosis; local vasoconstriction, microembolization, and inflammatory activation amplify ischemia. Coronary angiography performed after resolution may show a stenosis less dramatic than the event, whereas OCT may document cap discontinuity or residual thrombus. However, not every irregular lesion is the culprit: attribution must correspond to the territory, ECG, and clinical presentation.

A critical fixed stenosis may cause variable-threshold angina when small changes in heart rate, pressure, or vascular tone exceed reserve. Atherosclerotic progression, intraplaque hemorrhage, and remodeling may rapidly narrow the lumen even without overt thrombus; left main disease, a proximal left anterior descending lesion, or disease of the last patent vessel makes an apparently modest reduction in flow dangerous. In multivessel disease, the ischemic area may be extensive and produce diffuse ST-segment depression. The absence of necrosis describes the cellular outcome up to that point, not benign anatomy.

Epicardial vasospasm may cause rest angina with transient ST-segment changes and negative troponin when brief; microvascular dysfunction may cause ischemia without obstructive stenoses. Both require assessment different from that for atherothrombosis and respond to calcium-channel blockers and nitrates rather than automatic PCI. Cocaine, amphetamines, triptans, and other vasoconstrictors may precipitate spasm. SCAD may present with ischemia without initial biomarker elevation, particularly when the territory is small or sampling is early. Transient emboli and intermittent stent thrombosis are less common but high-risk mechanisms.

Risk factors for atherothrombotic unstable angina are the same as those for coronary atherosclerosis: LDL and apoB, Lp(a), smoking, hypertension, diabetes, kidney disease, and family history. Previous infarction, PCI, or bypass surgery increases pretest probability and suggests complex anatomy; interruption of antiplatelet therapy after stenting, anemia, fever, infection, hypoxemia, and tachyarrhythmia may destabilize reduced reserve. In a presentation caused exclusively by a supply-demand imbalance, the precipitant should be described without postulating an acute plaque. Probability must also be calibrated for age, sex, and context, avoiding stereotypes.

During ischemia, reduced ATP first impairs diastolic relaxation, then contraction and electrical stability. Metabolites such as adenosine, lactate, and bradykinin activate afferent fibers and cause pain; autonomic function, diabetic neuropathy, and the individual threshold explain different symptoms at the same flow level; ST-segment depression reflects a subendocardial injury vector, whereas T-wave inversions follow repolarization abnormalities. If flow is restored before irreversible injury, the myocardium remains viable and troponin does not meet the criteria. Repeated episodes may nevertheless cause stunning and transient dysfunction.

The biological boundary between angina and infarction also depends on the analytical limit. The 99th percentile varies among assays and must be sex-specific; samples obtained too early or at inappropriate intervals produce false classification. With a sensitive assay, true unstable angina should have serial values that do not meet the definition of acute injury. Chronically elevated troponin due to kidney disease or heart disease does not automatically make the presentation NSTEMI: a dynamic change and evidence of ischemia are required. Conversely, a small change compatible with infarction must not be ignored because the peak is low. Diagnosis is therefore clinical and analytical and depends on the quality of the entire pathway.

Myocardial demand may destabilize an otherwise compensated stenosis. Fever, hyperthyroidism, hypertension, and unusual exertion increase heart rate and wall tension; anemia and hypoxia reduce supply; if necrosis with evidence of ischemia occurs in the context of another acute condition causing supply-demand imbalance, the presentation may constitute secondary myocardial infarction rather than unstable angina. Without necrosis, secondary ischemia is described and the precipitant specified. Precise terminology prevents every episode from being attributed to plaque thrombosis.
Systemic inflammation may activate the endothelium and coagulation, but markers such as CRP do not identify the individual culprit plaque. An elevated value adds information about overall risk and may reflect infection or chronic disease; no blood biomarker can confirm unstable angina in the absence of troponin elevation. Diagnosis remains based on demonstration of reversible ischemia.

Coronary reserve integrates epicardial stenosis, the microcirculation, perfusion pressure, and demand. Two patients with the same angiographic percentage may have different thresholds because of collateral circulation, ventricular mass, and endothelial function. FFR during an unstable phase may be influenced by the microcirculation, whereas iFR avoids hyperemia but not all acute limitations. Physiology is more reliable for nonculprit lesions after stabilization.
A transient thrombus may embolize without producing a measurable peak if the mass is minimal or sampling is remote, but with high-sensitivity assays true necrosis must be classified as infarction; knowing the limits and precision of the assay is therefore essential. A laboratory should not use different thresholds without validation. Communication between clinician and laboratory prevents diagnoses based on incorrect units or percentiles.

Clinical classification, anatomy, and evolution

Traditional descriptions distinguish rest angina, severe new-onset angina, and crescendo angina. Worsening concerns frequency, duration, intensity, threshold, or response to nitrates; a single mild episode with predictable exertion does not meet the syndrome; the Braunwald classification integrated severity, circumstances, and treatment, separating secondary, primary, and post-infarction forms. It remains historically useful, but modern biomarkers and contemporary stratification have reduced its decision-making role. Vasospastic angina and microvascular angina are mechanistic phenotypes that may behave unstably without atherothrombosis.

Anatomically, disease may involve a single vessel, multiple vessels, the left main, a graft, or a stent. Severe stenosis does not prove that the episode originated from it, particularly when multiple plaques are present; moderate stenosis does not exclude transient thrombosis that has already resolved; ostial lesions, bifurcations, calcification, and degenerated bypass grafts influence risk and the choice between PCI and surgery. In patients without obstructions, vasomotor testing and coronary physiology may reveal spasm or microvascular dysfunction. Angiography maps the lumen; it does not fully reconstruct pathogenesis.
The ECG may show dynamic ST-segment depression, T-wave inversion, transient elevation, or normal findings. Changes in multiple leads during pain increase probability and risk; their disappearance after nitrates demonstrates reversibility but does not establish the cause; deep, symmetric anterior T waves in a patient who is now asymptomatic may suggest the Wellens pattern and a critical left anterior descending lesion, making exercise testing dangerous. Depression in V1-V3 may mirror posterior ischemia and requires V7-V9. A normal tracing between episodes is common and does not exclude the condition.

The most feared evolution is progression to NSTEMI or STEMI. Thrombosis may become persistent, a stenosis may occlude, or spasm may become prolonged; the appearance of a troponin dynamic reclassifies the event as infarction without making the preceding surveillance incorrect; some presentations resolve with treatment and do not recur, whereas others reveal diffuse coronary artery disease with high late risk. Prognosis depends more on the probability that the diagnosis is truly ischemic and on the substrate than on the name. Older cohorts built with less sensitive assays overestimate the risk of the current troponin-negative category.

Clinical stabilization does not mean plaque healing. Endothelialization, thrombus organization, and healing may restore a stable surface, but subclinical episodes of rupture and healing contribute to stenosis progression; after revascularization, risk depends on stent expansion, adherence, and nonculprit plaques; after medical treatment, it depends on lipid control, smoking, blood pressure, and the vasomotor mechanism. A new episode requires reassessment because the phenotype may have changed. Recurrence must not automatically be attributed to anxiety or reflux.
The concept of unstable angina ultimately requires a final classification. If CMR demonstrates myocarditis, if coronary CT angiography excludes coronary artery disease in a low-risk patient, or if a noncardiac cause explains the pain, the coding must be corrected. If a troponin dynamic and ischemia emerge, the diagnosis becomes NSTEMI; if persistent ST-segment elevation appears, the pathway is STEMI. If the coronary arteries are nonobstructive but ischemia remains convincing, spasm and the microcirculation warrant dedicated assessment. Retaining a provisional label obscures prognosis and treatment. Diagnostic precision is part of safety.

Early post-infarction angina indicates ischemia in the culprit territory or other vessels and has a different significance from pericarditic pain. It may result from residual thrombus, dissection, no-reflow, or incomplete revascularization; new ECG changes during symptoms point toward coronary angiography. Troponin that remains elevated requires assessment of a new change for reinfarction. Persistent biomarker elevation does not make clinical diagnosis irrelevant.
After bypass surgery, ischemic instability may arise from a degenerated vein graft, an anastomosis, or native-vessel progression. The ECG localizes imperfectly because of collateral circulation and altered territories, and coronary CT angiography may assess patency in stable patients; at high risk, invasive coronary angiography remains the therapeutic route. The previous operative report reduces procedure time and contrast use. PCI of the native vessel is preferred when reasonable.

Transition to a stabilized chronic condition requires disappearance of ischemia at rest, optimized treatment, and an anatomical or functional plan. The absence of recurrent pain for a few hours is insufficient; a chronic coronary syndrome is diagnosed after the acute phase and not retrospectively to minimize the presentation. Early recurrence indicates that the mechanism is not controlled.
A left main lesion may cause diffuse ischemia, ST-segment depression in multiple leads, and instability. Elevation in aVR increases suspicion of global ischemia but is not specific and does not replace angiography; multivessel disease, tachycardia, and hypotension may produce the same pattern. The urgent decision is based on persistence and hemodynamic status. An electrocardiographic label does not automatically determine the vessel.

Clinical manifestations

The central symptom is pressing, heavy, burning, or constricting retrosternal discomfort that occurs at rest, awakens the patient from sleep, or appears with exertion that was previously well tolerated. It may radiate to one or both arms, the shoulders, jaw, neck, back, or epigastrium; a prolonged episode lasting more than twenty minutes, a crescendo sequence, or a reduced response to nitrates increases suspicion. The description “pain” is not required: many patients report heaviness, pressure, or shortness of breath. Intensity and radiation do not distinguish angina from NSTEMI.
Dyspnea, sweating, nausea, pallor, and weakness reflect an autonomic response or transient dysfunction. Older people and patients with diabetes or kidney disease may present with dyspnea, syncope, or confusion without recognized pain; women often report pain with more accompanying symptoms; palpitations may be a consequence or precipitant of ischemia. Syncope requires investigation for arrhythmia, aortic stenosis, pulmonary embolism, and neurological causes in addition to coronary artery disease. The absence of symptoms at assessment is common because the process may be intermittent.

The history compares the episode with the usual pattern: threshold, duration, frequency, triggers, and response. Angina after PCI raises concern for restenosis or thrombosis; after bypass surgery, graft disease or native-vessel progression; shortly after infarction, post-infarction ischemia; smoking, diabetes, dyslipidemia, and family history increase probability, but their absence does not exclude a coronary mechanism. Cocaine and stimulants point toward vasospasm and thrombosis; fever, bleeding, and tachyarrhythmia suggest a secondary imbalance. Medications and adherence are part of the causal history.
Physical examination seeks high-risk signs. Hypotension, hypoperfusion, crackles, a third heart sound, hypoxemia, or new mitral regurgitation are incompatible with accelerated discharge; they may indicate extensive ischemia or infarction not yet biomarker-positive; severe hypertension increases demand and may cause pain, but does not exclude an acute plaque. Pulse asymmetry, aortic regurgitation, and back pain suggest dissection; tachycardia, hypoxia, and venous signs suggest pulmonary embolism. Chest-wall tenderness makes a musculoskeletal cause more likely without excluding coexistence.

Refractory or recurrent pain, particularly with dynamic ST-segment depression, requires an immediate invasive strategy. Life-threatening arrhythmias, hemodynamic instability, and acute heart failure also place the patient at very high risk regardless of the first troponin result; a normal ECG and low serial troponin values instead permit clinical risk assessment. HEART and EDACS may help in chest-pain pathways, whereas GRACE is better suited to prognosis in confirmed ACS. No score corrects samples obtained too early or an unmistakably ischemic history that has been ignored.
The clinical differential diagnosis includes reflux, esophageal spasm, chest-wall pain, pericarditis, myocarditis, Takotsubo syndrome, pulmonary embolism, and acute aortic syndrome. Pleuritic or positional pain reduces the probability of angina but does not eliminate it; relief with an antacid or nitrate is not discriminatory; anxiety and hyperventilation may mimic or accompany ischemia. The objective is not to find a pathognomonic adjective, but to integrate probability, ECG, biomarkers, and clinical course. Recurrence observed in a monitored setting provides valuable diagnostic information.

Nocturnal angina may reflect increased venous return, autonomic changes, or vasospasm. Awakening from sleep is suggestive but nonspecific because reflux and sleep apnea produce similar symptoms; recording the time, response, and ECG changes helps identify vasomotor periodicity. Obstructive sleep apnea is also a risk factor and possible precipitant.
An anginal equivalent may be dyspnea due to transient diastolic dysfunction, fatigue, or a sudden reduction in capacity. Reproducibility at a low threshold and recovery with rest increase probability; in patients unable to communicate, instability, sweating, and ECG changes carry greater weight. Comparison with relatives or caregivers may reconstruct a functional change.

Assessment must include occult bleeding, NSAID use, cocaine, stimulants, erectile-dysfunction drugs, and adherence. Nitrates after PDE5 inhibitors may cause severe hypotension. Interruption of a P2Y12 inhibitor after stenting increases thrombosis risk, whereas active hemorrhage makes empirical antithrombotic therapy dangerous. Medication reconciliation is a diagnostic act.
Symptom variability is informative. Episodes at the same time while at rest with transient ST-segment changes suggest a vasomotor mechanism; a progressively lower threshold with activity suggests reduced fixed reserve; random pain lasting seconds is less compatible; no pattern is absolute. A diary may help after discharge only once the emergency has been excluded. During the acute phase, the patient must not deliberately test the threshold.

Investigations and diagnosis

The ECG must be recorded within minutes and repeated during symptoms. The most convincing evidence is a dynamic ischemic change: horizontal or downsloping ST-segment depression, regional T-wave inversion, or transient elevation consistent with the pain; baseline abnormalities due to hypertrophy, block, pacing, digitalis, and electrolytes reduce specificity; comparison with previous tracings is essential. Posterior and right-sided leads extend coverage when suggested by the location. A completely normal ECG does not exclude ischemia, but lowers risk within a coherent serial pathway.
High-sensitivity troponin is interpreted with a validated serial algorithm at 0/1 hour or 0/2 hours for the specific assay. A very low initial value and minimal delta may support rule-out if onset was not too recent; intermediate results require observation, a new sample, and clinical judgment; to diagnose unstable angina, there must be no acute myocardial injury meeting the definition of infarction. Chronically elevated values require analysis of the change, whereas a significant delta with ischemia leads to NSTEMI. Thresholds cannot be transferred between laboratories or between troponin I and T.

Elements required for a clinically sustainable diagnosis of unstable angina

• Symptoms compatible with acute myocardial ischemia at rest or with minimal exertion, either severe new-onset symptoms or clearly worsening symptoms.
• Absence of persistent ST-segment elevation requiring a STEMI reperfusion pathway.
• Serial high-sensitivity cardiac troponin that does not meet the criteria for acute myocardial injury and infarction, with sampling times appropriate to onset.
• Probability of ischemia supported by a dynamic ECG, known coronary artery disease, imaging, anatomy, or clinical course; reasonable exclusion of the principal alternative diagnoses.

Echocardiography assesses regional wall motion, ejection fraction, valves, and alternative diagnoses. A transient abnormality during pain strengthens the diagnosis of ischemia, but a normal examination between episodes does not exclude it. New mitral regurgitation, global dysfunction, or effusion changes urgency and diagnosis; complete blood count, creatinine, electrolytes, glucose, and coagulation tests identify precipitants and treatment risk. BNP describes hemodynamic stress but does not distinguish angina from infarction. Chest radiography, D-dimer, and aortic or pulmonary CT angiography are guided by a specific alternative probability.
Invasive coronary angiography is indicated rapidly in very-high-risk patients and during hospitalization when ischemia is recurrent or the probability of a treatable lesion is high. It defines anatomy and permits PCI, but may show nonculprit stenoses or nonobstructive coronary arteries; OCT, IVUS, FFR, and iFR are used selectively. In stable low-to-intermediate-risk patients, coronary CT angiography has high value for excluding obstructive disease and reducing unnecessary hospitalization. Severe calcification, stents, tachycardia, and kidney disease may limit it. Functional testing is appropriate only after infarction has been excluded and in the absence of high-risk signs.

Exercise testing must not be performed with active ischemia, recurrent pain, dynamic abnormalities, or a suspected Wellens pattern. In selected stable patients, exercise ECG, stress echocardiography, nuclear perfusion imaging, or CMR may document inducible ischemia and guide angiography; the choice depends on the baseline ECG, exercise capacity, probability, radiation, and availability. A good-quality negative result lowers risk, whereas a nondiagnostic test must not be called normal. Safe discharge requires a plan, not merely a report.
The final diagnosis must avoid two opposite errors: overdiagnosis of indeterminate pain and underdiagnosis of troponin-negative ischemia. If angiography shows an acute plaque or a consistent critical stenosis, the diagnosis is solid; if testing excludes ischemia, the most likely cause should be recorded; if the coronary arteries are nonobstructive and symptoms persist, testing for spasm and the microcirculation may identify ANOCA. If troponin becomes positive, the infarction pathway applies and, in the absence of obstructions, the MINOCA pathway. Clarity prevents unnecessary DAPT or, conversely, inadequate prevention.

Rule-out algorithms have high negative predictive value when applied to the populations and assays in which they were validated. A value below the limit of detection may permit exclusion with the first sample only when sufficient time has elapsed since onset and the ECG is nonischemic; very early pain requires a serial sample. Ruling out infarction is not equivalent to excluding ischemia. Clinical disposition depends on the residual probability.
Coronary CT angiography describes the lumen and plaque and is highly useful in patients without known coronary artery disease at low-to-intermediate risk. A good-quality examination showing no plaque makes obstructive atherosclerosis unlikely, but does not exclude spasm or microvascular disease; calcification, stents, and a rapid rhythm reduce accuracy. An intermediate stenosis may require physiology or functional testing. The result must change management to justify contrast and radiation.

Stress CMR or stress echocardiography demonstrates inducible ischemia and function without directly defining the plaque. Nuclear perfusion is robust but involves radiation; exercise ECG is less accurate and requires an interpretable tracing and physical capacity; testing is selected rather than accumulated according to the clinical question. An equivocal result must not be converted into reassurance. Technical quality must appear in the report.
Diagnostic observation must have an endpoint. Repeating troponin beyond the algorithm without new symptoms does not increase safety indefinitely and may detect unrelated changes; at completion, discharge, testing, coronary CT angiography, or invasive angiography is chosen according to residual probability. An unresolved case is handed over with an explicit timeframe and responsibility. Continuity reduces return visits and missed diagnoses.

Treatment and prognosis

Immediate treatment depends on probability and severity. Aspirin is given promptly when NSTE-ACS is probable and there is no bleeding or severe allergy; monitoring is proportionate to pain, ECG findings, and instability; nitrates reduce ischemia when blood pressure and preload allow, beta-blockers control heart rate and demand in stable patients, and calcium-channel blockers are useful in spasm or when beta-blockers are not tolerated. Oxygen is reserved for hypoxemia. Symptom relief does not replace anatomical definition in high-risk profiles.
The choice of a P2Y12 inhibitor and anticoagulant requires greater caution than in confirmed NSTEMI. If the diagnosis is uncertain and coronary angiography is planned, pretreatment may cause bleeding or delay bypass surgery without certain benefit; the decision follows probability, invasive timing, and risk; when angiography demonstrates a culprit lesion treated with PCI, DAPT follows ACS recommendations. In medically managed true unstable angina, clopidogrel or ticagrelor may be appropriate according to risk; a diagnosis that is subsequently disproved requires reassessment. Fibrinolysis is not indicated.

Refractory pain, instability, arrhythmias, or heart failure requires immediate coronary angiography. In stable patients with dynamic changes, known coronary artery disease, or a high probability of a critical lesion, an invasive strategy during hospitalization permits treatment before necrosis develops. PCI and bypass surgery depend on anatomy, complexity, diabetes, ventricular function, and the possibility of complete revascularization. Radial access and drug-eluting stents reduce complications when PCI is performed. A procedure should not be imposed if imaging excludes an epicardial cause and the mechanism is vasomotor.
At low risk, after reassuring serial troponin and ECG findings, an accelerated pathway may avoid hospitalization and procedures. Coronary CT angiography or functional testing is selected according to probability; some very-low-risk patients do not require immediate testing but do require reliable clinical follow-up; discharge includes clear instructions about recurrence and correction of risk factors. A low score does not authorize discharge if pain continues or sampling is inadequate. Observation must not become indefinite repetition of tests without a diagnostic question.

If atherosclerosis is documented, secondary prevention includes a high-intensity statin, combination therapy according to LDL, smoking cessation, blood-pressure and diabetes control, physical activity, and rehabilitation. An ACE inhibitor or ARB is indicated for hypertension, diabetes, kidney disease, dysfunction, or heart failure; antianginal therapy is tailored to symptoms. Calcium-channel blockers and nitrates are central in spasm, with avoidance of smoking and vasoconstrictors; in microvascular dysfunction, treatment is endotype-specific. Treatment of one stenosis does not eliminate the risk from other plaques. Adherence and tolerability are checked early.

The prognosis of contemporary true unstable angina is generally better than that of NSTEMI, but is not uniform. Repeatedly low troponin, a normal ECG, no coronary artery disease, and reassuring testing identify lower risk; dynamic ST-segment depression, previous revascularization, diabetes, and critical anatomy increase it. Estimates from historical studies include many events that would now be NSTEMI and are not directly transferable. In the long term, prognosis follows atherosclerotic burden and the quality of prevention. Success means not only avoiding infarction during hospitalization, but also preventing recurrence and unnecessary procedures.
Antianginal therapy is titrated according to blood pressure. Beta-blockers are useful with tachycardia and previous infarction; calcium-channel blockers control spasm or residual symptoms; long-acting nitrates require a nitrate-free interval to limit tolerance; ranolazine may reduce symptoms without major effects on heart rate and pressure, but does not replace revascularization of an unstable lesion. Prognostic and symptomatic effects must be distinguished.

In patients at high bleeding risk, DAPT selection and duration are individualized after anatomy is known. Age, anemia, kidney disease, previous hemorrhage, and anticoagulation increase risk; stent complexity and ACS increase thrombotic risk; an abbreviated strategy may be appropriate after modern PCI, but must not be improvised during bleeding without considering the time since stenting. Gastroprotection is indicated in appropriate profiles.
Cardiac rehabilitation is indicated after ACS and revascularization and may aid functional recovery even after medical management. Supervised exercise, smoking cessation, nutrition, and psychological support act together; fear of causing an infarction often leads to inactivity. A gradual prescription replaces generic prohibitions. Return to activity is based on stability and capacity.

Complete revascularization does not mean treating every irregularity. Significant stenoses, ischemia, territory, function, and technical feasibility are considered; bypass surgery may be preferable in left main or complex multivessel disease; a staged procedure permits stabilization and decision-making, whereas immediate additional PCI may increase contrast use. The objective is to reduce ischemia and risk, not to obtain a perfect angiogram. Informed preferences enter the choice.

Complications

The defining complication is progression to myocardial infarction. The appearance of a troponin dynamic with evidence of ischemia defines NSTEMI; persistent occlusion with ST-segment elevation or an equivalent activates STEMI reperfusion. Evolution may occur while pain is intermittent and the first ECG was normal. Monitoring and repeated testing are not formalities, but tools for detecting this change. Increasing pain, instability, or new abnormalities must not await the next sample. A spontaneously recanalized vessel may occlude again.
Ischemic arrhythmias include ectopy, ventricular tachycardia, ventricular fibrillation, atrial fibrillation, and bradyarrhythmias. They are less common without extensive necrosis, but severe ischemia may be electrically unstable before biomarker release; syncope, palpitations, and dynamic abnormalities require telemetry. Correction of flow and potassium or magnesium is the priority; antiarrhythmic drugs do not replace treatment of ischemia. An arrhythmia may also be the precipitant of an imbalance, requiring causal reconstruction.

Acute heart failure may result from extensive ischemia, diastolic dysfunction, transient mitral regurgitation, or an arrhythmia. Crackles, hypoxia, and low output make echocardiography and angiography urgent; pulmonary edema with an initially negative troponin must not be trivialized; shock and mechanical complications often suggest that necrosis is already present or another diagnosis and require repeated biomarkers and imaging. Recovery after revascularization may be rapid when stunning predominates. Preserved function does not exclude high filling pressures.
Treatment may cause bleeding, thrombocytopenia, hypotension, and kidney injury. Treating every indeterminate pain as ACS exposes patients to harm without benefit; conversely, prematurely stopping antiplatelet therapy after culprit PCI exposes them to thrombosis; radial access, adjusted doses, selected gastroprotection, and individualized antithrombotic duration reduce risk. If oral anticoagulation is necessary, overlap with DAPT should be brief. Occult bleeding may also cause ischemia through anemia.

Coronary angiography may cause dissection, perforation, embolization, procedural infarction, stroke, or kidney injury; the risk is low but relevant when the indication is weak. Suboptimal PCI may cause restenosis or thrombosis, whereas bypass surgery entails perioperative risk and requires antiplatelet planning; these possibilities do not justify delay in high-risk patients, but reinforce selection in low-probability cases. Intravascular imaging and radial technique improve safety. Informed consent should be proportionate to urgency.
In the long term, recurrent angina, atherosclerotic progression, infarction, stroke, and heart failure depend on anatomy and prevention. Persistent symptoms with nonobstructive coronary arteries may reflect spasm or microvascular disease and must not be labeled imaginary; conversely, noncardiac pain may continue after unnecessary PCI. Anxiety after an emergency visit is common and may reduce activity and quality of life. A clear diagnostic explanation, rehabilitation, and follow-up reduce uncertainty and repeated visits. The most avoidable organizational complication is a vague diagnosis that perpetuates incorrect treatment.

Stent thrombosis must be considered in any acute pain after PCI, particularly after DAPT interruption. It may present as STEMI, NSTEMI, arrhythmia, or death and requires urgent angiography. OCT or IVUS identifies underexpansion, malapposition, and dissection after flow has been restored. Recurrence is prevented by correcting mechanics and treatment.
Refractory angina is not defined by a few episodes during titration, but by persistent symptoms despite treatment and inability to perform conventional revascularization. Before applying the label, diagnosis, adherence, anemia, blood pressure, microvascular disease, and noncardiac pain must be reassessed; dedicated programs reduce hospitalization and improve quality of life. Repeated PCI without a target may worsen the problem.

Overdiagnosis is a clinical complication: unnecessary DAPT, hospitalization, procedures, and permanent fear. Underdiagnosis instead exposes patients to infarction and death; reducing both requires correctly interpreted high-sensitivity assays, selective testing, and an explicit final diagnosis. Terminological precision provides a concrete benefit to the patient.
Recurrence after discharge requires a clear plan: call emergency services for persistent pain or associated symptoms, do not drive to the hospital, and do not use nitrate response as a diagnostic test; the patient must know which drugs to take and when not to repeat them because of hypotension. Follow-up that is too distant misses the period of greatest risk. Education and accessibility are preventive measures.